Privia Health Group (PRVA) Q2 2024 earnings summary

Executive summary

• Achieved strong execution across all business and financial metrics in Q2 2024, with robust growth in implemented providers (up 16.4% to 4,504) and attributed lives (up 10.7% to 1.2 million), and continued expansion across 13 states and DC.

• Practice Collections reached $728.0M, a 4% year-over-year increase, and adjusted EBITDA grew 14% to $22.0M in Q2 2024.

• Net income for Q2 2024 was $3.5M, down from $7.3M in Q2 2023, impacted by higher non-cash stock compensation expense.

• Maintained high provider retention (over 98% gross) and high patient satisfaction (Net Promoter Score of 85).

• Raised full-year 2024 guidance to the mid to high end for all metrics, reflecting high visibility and confidence in the business outlook.

Financial highlights

• Q2 2024 revenue grew 2.2% year-over-year to $422.3M; gross profit up 8.9% to $98.3M.

• Adjusted EBITDA for the first half of 2024 was $41.9M, up 15.9% from the prior year period.

• Care Margin for Q2 2024 was $99.8M, up 8.9% year-over-year; Platform Contribution was $47.4M, up 6.2%.

• Cash and cash equivalents at $387.4M as of June 30, 2024, with no debt.

• Stock-based compensation expense for Q2 2024 was $14.4M, up from $9.2M in Q2 2023.

Outlook and guidance

• Full-year 2024 guidance raised to mid to high end for all metrics, including revenue ($1.6B–$1.675B), care margin ($388M–$400M), and adjusted EBITDA ($85M–$90M).

• Practice Collections guidance reflects a $198M year-over-year reduction due to renegotiated MA capitation agreements.

• Approximately 80% of adjusted EBITDA expected to convert to free cash flow in FY 2024.

• Second half of the year expected to be stronger, with significant shared savings payments anticipated.

• Cash position expected to reach $425M–$450M by year-end if no major investments are made.